TY - JOUR
T1 - Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study)
T2 - A randomized clinical trial
AU - Gulley, Emma
AU - Verghese, Joe
AU - Blumen, Helena M.
AU - Ayers, Emmeline
AU - Wang, Cuiling
AU - Portenoy, Russell K.
AU - Zwerling, Jessica L.
AU - Weiss, Erica
AU - Knotkova, Helena
N1 - Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT 04404153 (Clinicaltrials.gov).
AB - New therapies for symptoms in Alzheimer's disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT 04404153 (Clinicaltrials.gov).
KW - Alzheimer's disease
KW - at-home tDCS
KW - clinical trial protocol
KW - dementia
KW - noninvasive neurostimulation
KW - transcranial direct current stimulation (tDCS)
UR - http://www.scopus.com/inward/record.url?scp=85115114702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115114702&partnerID=8YFLogxK
U2 - 10.2217/nmt-2020-0061
DO - 10.2217/nmt-2020-0061
M3 - Article
C2 - 34240627
AN - SCOPUS:85115114702
SN - 1758-2024
VL - 11
SP - 277
EP - 288
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 4
ER -